Gene test + MRI may spare men from full prostate removal
NCT ID NCT04541030
First seen Jan 06, 2026 · Last updated Jun 20, 2026 · Updated 27 times
Summary
This study looks at whether combining a genetic test called the Oncotype DX Genomic Prostate Score (GPS) with MRI scans can help doctors choose men with prostate cancer for focal therapy—a treatment that targets only the cancer, leaving healthy tissue alone. Researchers will review past data and tissue samples from 241 men with low- or intermediate-risk prostate cancer. The goal is to see if the GPS score, together with MRI findings, can better predict which men have aggressive cancer that needs more extensive treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Institute (NCI)
Bethesda, Maryland, 20892, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors more accurately choose which men with prostate cancer can safely have focal therapy instead of full prostate removal, potentially reducing side effects.
What could go wrong
This is a retrospective study using existing data and samples, not a treatment trial. It may not prove that GPS and MRI together work better in practice, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.